Covered Entities are Forced to Choose between 340B Drug Discounts and Their Patient’s Data Privacy

Audrey Ernst 

Associate Editor 

Loyola University Chicago School of Law, JD 2028 

Eli Lilly, a prominent pharmaceutical manufacturer, now faces legal action from five Massachusetts hospitals. Independently, each plaintiff hospital was denied 340B discounts on drugs manufactured by Eli Lilly for failing to comply with the manufacturer’s new patient claims data requirements (PCDR) which were established in early 2026. The hospitals allege that this was an illegal action that will lead to annualized overpayments of at least $20 million by forcing them to pay exorbitant inflated drug prices that deprive them of essential resources. The hospitals refused to comply with Eli Lilly’s PCDR because they believed doing so would violate their patients privacy protections established under the Health Insurance Portability and Accountability Act (HIPAA). The scope of legal action in response to the PCDRs displays a need for federal action to ensure that pharmaceutical manufacturers cannot withhold federal program benefits on their own without federal consent.  

340B Drug Pricing Program: How drug manufacturers reshaped access and compliance 

The 340B Drug Pricing Program (340B), since its 1992 inception, has been a lifeline to financially struggling covered entities that focus on providing care to underserved populations at the lowest possible cost. 340B allows for qualifying covered entities (QCE) and contract pharmacies under the program to purchase certain pharmaceuticals from manufacturers participating in Medicaid at reduced ceiling prices. The prices are set by the HRSA and then billed for at standard drug manufacturer rates through federal healthcare programs (Medicare and Medicaid). The reduced prices were established to allow QCEs to stretch their resources to serve disadvantaged populations by reducing their operational costs and to pay for services that go uncompensated due to a patient’s inability to pay. Without this program, many 340B qualified hospitals are at risk of closure. 

Despite the Health Resource and Services Administration (HRSA) working as the administrator of 340B, the QCEs are seemingly beholden to the power of the large pharmaceutical manufacturers, whose burdensome compliance requirement obligations have now provided them with an impossible choice. The Eli Lilly Data PCDRs force hospitals to choose between complying with potentially unlawful patient data disclosures or be cut off from 340B discounts altogether. 

While 340B is believed to have led to millions of dollars in savings for QCEs, it has not operated without criticism. Specifically, Eli Lilly suggests certain entities have overutilized drug pricing discounts, along with an overall lack of transparency. Currently, 340B includes specific audit requirements for QCEs, yet pharmaceutical manufacturers claim the data does not provide necessary information. Eli Lilly’s Data Requirements arose from this lack of transparency, as they believe 340B is being exploited. Furthermore, Eli Lilly has stated the data requested from the plaintiff hospitals is standard information frequently provided to insurers as business associates under HIPAA. The necessity of the PCDRs has been supported by Eli Lillyis own audit data that shows frequent duplicate discounts on drugs they provide. Navigating this evolving compliance framework has led to legal action across several circuits, prompting QCEs to seek protective rulings from federal and state courts. Some lawsuits allege PCDRs, such as Eli Lilly’s Data Requirements, violate state law and block QCEs from accessing statutorily granted 340B discount rates. Concurrently, the federal circuits’ analysis of the issue has led to multiple conclusions on the legality of PCDRs, which now risks interference with HRSA’s ability to adminsiter 340B.  

Protecting the integrity of 340B while restoring participation 

Despite the consequential loss of 340B discounts, hospitals have made the decision to seek legal action rather than complying with drug manufacturers’ PRDCs, a choice that could lead to further losses of critically needed 340B discounts. This is due to the fact that plaintiff hospitals fear they may violate HIPAA requirements, as illustrated by the most recent lawsuit filed in Massachusetts. Under HIPAA, a covered entity may only disclose patient health information (PHI) to authorized business associates under certain conditions. In the case of the Massachusetts hospitals, the plaintiff hospitals claim that the submission portal used by Eli Lilly is run by a third party not covered under HIPAA. This leaves the submitted information vulnerable to reidentification, which would make it an unlawful disclosure by the hospital. The HRSA has vocalized its disagreement with excessive drug manufacturer requirements in the past; however, HRSA is limited to policy guidance and restricted adjudicative action, thus legislative and judicial authorities must resolve whether the PCDRs are legal.  

As courts seek to resolve the legality of the disclosure requirements set by drug manufacturers, the access to medical care for many underserved communities is at risk, as 340B discounts provides needed funds to continue care for underserved communities. Furthermore, HRSA’s lack of rulemaking authority has become a significant setback for the protection of QCEs, as the PRDCs, since their enactment early this year, have not faced any significant scrutiny from the HRSA or other federal actors as of present. One solution to the issue at hand would be granting statutory rulemaking authority to the HRSA, so it may block such burdensome requirements by pharmaceutical manufacturers.  

As of now, these issues will need to be resolved through the federal court system. But what remains clear is that pharmaceutical manufacturers carry a great deal of power in granting discounts under 340B to place hospitals in a significantly vulnerable position without the means to efficiently and quickly defend themselves. The vulnerability faced by 340B qualifying covered entities goes against the purpose of 340B itself, which is to financially support covered entities to continue to serve safety net communities across the country. The fallibility within the program created by PRDCs has unveiled that the lack of enforcement discretion for the HRSA places 340B discount control in the manufacturers. This aspect of the program needs to be amended so that 340B qualified covered entities may continue to rely upon 340B discounts in the future.